Intellia Therapeutics Stock In Focus As HAE Gene Editing Wins Priority Review

Intellia Therapeutics is progressing from research to potential commercialisation with a priority FDA review of its CRISPR therapy lonvo z for hereditary angioedema and nearing Phase 3 completion for its nex z therapy in transthyretin amyloidosis, highlighting a high-stakes transition in rare disease treatment development.

This Wire brief sits within Fusion42's coverage of Biotech.